

6. (Amended) An expression vector comprising a polynucleotide which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:12 and (b) the amino acid sequence encoded by a cDNA insert contained within plasmid pCRII-TMSP3 (ATCC Accession No. PTA-3433).

11. (Amended) A host cell comprising an expression vector which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:12 and (b) the amino acid sequence encoded by a cDNA insert contained within plasmid pCRII-TMSP3 (ATCC Accession No. PTA-3433).

22. (Amended) A method of producing a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:12 and (b) the amino acid sequence encoded by a cDNA insert contained within plasmid pCRII-TMSP3 (ATCC Accession No. PTA-3433), comprising the steps of:

culturing a host cell comprising an expression vector that encodes the polypeptide under conditions whereby the polypeptide is expressed; and  
isolating the polypeptide.

27. (Amended) A kit for detecting a coding sequence for a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:12 and (b) the amino acid sequence encoded by a cDNA insert contained within plasmid pCRII-TMSP3 (ATCC Accession No. PTA-3433), comprising:

a polynucleotide comprising at least 225 contiguous nucleotides selected from the group consisting of (a) a polynucleotide comprising the complete complement of the nucleotide

sequence shown in SEQ ID NO:11, (b) a polynucleotide comprising the complete complement of the coding sequence of the cDNA insert of plasmid pCRII-TMSP3 (ATCC Accession No. PTA-3433), (c) a polynucleotide that hybridizes under stringent conditions to (a) or (b), and (d) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a) to (c) due to the degeneration of the genetic code; and

instructions for detecting the coding sequence of the polypeptide.

62. (Amended) A pharmaceutical composition, comprising:

an expression vector encoding a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:12 and (b) the amino acid sequence encoded by a cDNA insert contained within plasmid pCRII-TMSP3 (ATCC Accession No. PTA-3433) and

a pharmaceutically acceptable carrier.

69. (Amended) An isolated polynucleotide selected from the group consisting of: (a) a polynucleotide encoding a protein that comprises the amino acid sequence of SEQ ID NO:12, (b) a polynucleotide comprising the sequence of SEQ ID NO:11, (c) a polynucleotide comprising a coding sequence of a cDNA contained within plasmid pCRII-TMSP3 (ATCC Accession No. PTA-3433), (d) a polynucleotide encoding a protein that comprises the amino acid sequence encoded by the cDNA of plasmid pCRII-TMSP3, (e) a polynucleotide which hybridizes under stringent conditions along the full length of a polynucleotide specified in (a) - (d), and (f) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a) - (e) due to the degeneration of the genetic code.